Qiansui International Group Co Ltd
Change company Symbol lookup
Select an option...
QIAN Qiansui International Group Co Ltd
BV Brightview Holdings Inc
PFE Pfizer Inc
MP Mp Materials Corp
WFG West Fraser Timber Co Ltd
MDT Medtronic PLC
ATMR^ Altimar Acquisition Corp II
AEG Aegon NV
MGP MGM Growth Properties LLC
WRB W R Berkley Corp
Go


Based in China
Company profile

Qiansui International Group Co Ltd, formerly Ariel Clean Energy Inc, is a shell company. The Company is engaged in seeking new business opportunities with business entities for merger with or acquisition of a target business. The Company may seek a business opportunity with entities that have commenced operations, or entities wishing to utilize the public marketplace in order to raise additional capital to expand business development activities, to develop a new product or service, or for other corporate purposes. The Company may acquire assets and establish subsidiaries in various businesses or acquire existing businesses as subsidiaries. In implementing a structure for a particular business acquisition or opportunity, the Company may become a party to a merger, consolidation, reorganization, joint venture or licensing agreement with another corporation or entity. The Company may also acquire stock or assets of an existing business. The Company does not have a source of revenue.

Closing Price
$1.23
Day's Change
0.00 (0.00%)
Bid
--
Ask
--
B/A Size
--
Day's High
1.23
Day's Low
1.23
Volume
(Heavy Day)
Volume:
550

10-day average volume:
418
550

ACAD ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of June 18, 2021 in the Class Action Filed on Behalf of Acadia Pharmaceuticals Inc. Limited Shareholders

6:19 am ET May 6, 2021 (Newsfile) Print

New York, New York--(Newsfile Corp. - May 6, 2021) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) alleging that the Company violated federal securities laws.

Cannot view this image? Visit: https://orders.newsfilecorp.com/files/7092/83128_792893_logo.jpg

Class Period: June 15, 2020 and April 4, 2021

Lead Plaintiff Deadline: June 18, 2021

Learn more about your recoverable losses in ACAD:

http://www.kleinstocklaw.com/pslra-1/acadia-pharmaceuticals-inc-loss-submission-form?id=15546&from=5

The filed complaint alleges that Acadia Pharmaceuticals Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) the materials submitted in support of the pimavanserin sNDA contained statistical and design deficiencies; (ii) accordingly, the pimavanserin sNDA lacked the evidentiary support that the Company had led investors to believe it possessed; (iii) the FDA was unlikely to approve the pimavanserin sNDA in its present form; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.

Shareholders have until June 18, 2021 to petition the court for lead plaintiff status. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

For additional information about the ACAD lawsuit, please contact J. Klein, Esq. by telephone at 212-616-4899 or click the link above.

J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

J. Klein, Esq.

Empire State Building

350 Fifth Avenue

59th Floor

New York, NY 10118

jk@kleinstocklaw.com

Telephone: (212) 616-4899

Fax: (347) 558-9665

www.kleinstocklaw.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/83128

comtex tracking

Earnings Calendar and Events Data provided by |Terms of Use| © 2021 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2021. All rights reserved.